-
While the Unichem acquisition seems expensive at first glance, a closer look shows Ipca can benefit if it sweats the acquired assets
-
IPCA, which was mainly known a few years ago for anti-malarial medications, is now having a significant contribution from non-anti-malarial medicines
-
Net Sales are expected to increase by 21.1 percent Y-o-Y (down 7.8 percent Q-o-Q) to Rs. 1,300 crore, according to Sharekhan.
-
Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies
-
FIPB has deferred 18 proposals including that of Sharekhan Ltd for transfer of compulsory convertible debentures (CCDs) and compulsory convertible preference shares (CCPs), held by IDFC Ltd to Baring Private Equity.
-
Cadila's price hike of HydroxyChloroquine (antimalarial drug) after IPCA and Ranbaxy exit will add 15 percent to FY16 EPS. The benefit of higher prices and market share is likely to reflect in December 14 quarter results, it adds.
-
Banks and pharma stocks added strength to the indices while metals and oil & gas were under tremendous selling pressure.
-
Brent crude dropped further below USD 83 a barrel, stretching losses into a fifth session, as weak economic data from top energy consumer China stoked worries about demand in a market that is already battling a deepening global supply glut.
-
AnandRathi has come out with its report on India healthcare. According to the research firm, EBITDA margins are expected to be stable at 22-23 percent during the quarter. "Cipla, Cadila Healthcare, Natco Pharma, and Unichem Laboratories are the top picks, says AnandRathi.
-
Technical analyst, Sudarshan Sukhani, s2analytics.com is mildly bullish on the Nifty.
-
The pharma story is similar both on the generic front as well as on local businesss so we like IPCA laboratories ays Gautam Chhaochharia, UBS India
-
Technical analyst, Sudarshan Sukhani, s2analytics.com says in the intermediate term the undercurrent for market is bearish.
-
In an interview to CNBC-TV18 technical analyst, Sudarshan Sukhani of s2analytics.com shared his reading on market and stocks across various sectors.
-
In an interview to CNBC-TV18, Independent Analyst, Ambareesh Baliga shared his reading and outlook on markets and specific stocks.
-
Prabhudas Lilladher has come out with its report on "India strategy & top ideas". Infosys, ICICI Bank, Wipro, Cairn India, Power Grid Corporation, Dr.Reddy's Laboratories, Adani Port & SEZ and Ranbaxy Laboratories are the stocks from large cap space
-
In an interview with CNBC-TV18, Prashant Nair, Director & Deputy Head of Research, Citi India gives his outlook on the pharma sector. He picks Ranbaxy, Lupin, Apollo Hospital and Ipca as preferred stocks and believes, they will outperform not just the market but also its peers from the pharma space.
-
Emkay Global Financial Services has come out with its report on pharma space. According to the research firm one can buy Glenmark and IPCA.
